MBX.TO · Microbix Biosystems Inc

-

Please sign in to comment on MBX.TO

1 Comment

Admin

4 years ago

Microbix Biosystems Inc is currently in a long term uptrend where the price is trading 8.8% above its 200 day moving average.

From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.

Microbix Biosystems Inc's total revenue rose by 54.3% to $3M since the same quarter in the previous year.

Its net income has increased by 122.4% to $131K since the same quarter in the previous year.

Finally, its free cash flow fell by 532.5% to $-462K since the same quarter in the previous year.

Based on the above factors, Microbix Biosystems Inc gets an overall score of 4/5.

Industry	Biotechnology
Exchange	TO
CurrencyCode	CAD
ISIN	CA59501P1045
Sector	Healthcare

PE Ratio	35.5
Target Price	0.8
Beta	0.62
Market Cap	50M
Dividend Yield	None

ABOUT

Microbix Biosystems Inc

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for enabling the collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. It also provides customer vial filling services. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.

MBX.TO · Microbix Biosystems Inc

-

Microbix Biosystems Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Microbix Biosystems Inc using a moving average strategy